✦ LIBER ✦

Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib

✍ Scribed by Wataya, Hiroshi; Okamoto, Tatsuro; Maruyama, Riichiroh; Seto, Takashi; Yamazaki, Koji; Tagawa, Tetsuzo; Fukuyama, Seiichi; Osoegawa, Atsushi; Ikeda, Jiro; Nishimura, Munetsugu; Yamanaka, Takeharu; Ichinose, Yukito

Book ID: 119320023
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 257 KB
Volume: 64
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2008.09.005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The EGFR mutation and its correlation wi

The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer

✍ Zhang, X.-T. 📂 Article 📅 2005 🏛 Oxford University Press 🌐 English ⚖ 301 KB

Predictive Factors for Interstitial Lung

Predictive Factors for Interstitial Lung Disease, Antitumor Response, and Survival in Non-Small-Cell Lung Cancer Patients Treated With Gefitinib

✍ Ando, M. 📂 Article 📅 2006 🏛 American Society of Clinical Oncology 🌐 English ⚖ 294 KB

PCNI9 NEW TARGETED THERAPY FOR PATIENTS

PCNI9 NEW TARGETED THERAPY FOR PATIENTS WITH PREVIOUSLY-TREATED ADVANCED NON-SMALL CELL LUNG CANCER—GEFITINIB (“IRESSA”)

✍ R de Peuter; A Antonisse; J van Loon; J Brown 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

Predictive and Prognostic Impact of Epid

Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non-Small-Cell Lung Cancer Patients Treated With Gefitinib

✍ Han, S.-W. 📂 Article 📅 2005 🏛 American Society of Clinical Oncology 🌐 English ⚖ 132 KB

Risk factors for interstitial lung disea

Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib

✍ Takano, Toshimi; Ohe, Yuichiro; Kusumoto, Masahiko; Tateishi, Ukihide; Yamamoto, 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 151 KB

Activity of ZD1839 (Gefitinib, Iressa™)

Activity of ZD1839 (Gefitinib, Iressa™) in Previously Treated Patients with Recurrent and Advanced non—small-Cell Lung Cancer

✍ Angelia D. Gibson; Mark Socinski; Chandra P. Belani; Vinay K. Jain 📂 Article 📅 2002 🏛 CIG Media Group, LP. 🌐 English ⚖ 79 KB